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Abstract 
X-linked adrenoleukodystrophy (X-ALD) is the most common inherited leukodystrophy. 
Nevertheless no genotype/phenotype correlation has been established yet. Unidentified 
modifier genes or other co-factors are suspected to modulate phenotype and prognosis. We 
recently described polymorphisms of methionine metabolism as possible disease modifiers in 
X-ALD.  
To retest these findings, we analyzed 172 new DNA- samples of X-ALD patients from 
different populations (France, Germany, USA, China) by genotyping the eight genetic 
variants of methionine metabolism including DHFR c.594+59del19bp, CBS c.844_855ins68, 
MTR c.2756A>G, MTHFR c.677C>T and c.1298A>C, MTRR c.60A>G, RFC1 c.80G>A, 
and Tc2 c.776C>G. We compared the three X-ALD phenotypes childhood onset cerebral 
demyelinating inflammatory type (CCALD; n=82), adulthood onset with focal cerebral 
demyelination (ACALD; n=38), and adulthood onset without cerebral demyelination (AMN; 
n=52). Association of genotypes and phenotypes was analyzed with univariate two sided 
Pearson`s χ2.  
The G-allele of Tc2 c.776C>G was associated with X-ALD phenotypes in the comparison 
between AMN and CCALD (2=6.1; p=0.048). The prevalence of the GG- genotype of Tc2 
c.776C>G was higher in patients with CNS demyelination compared to those without CNS-
demyelination (2=4.42; p=0.036). The GG- genotype was more also more frequent in 
CCALD compared to AMN (2=4.7; p=0.031). The other polymorphisms did not reveal 
significant associations in this study sample.  
Whereas any influence of other polymorphisms of methionine metabolism was not confirmed, 
the present study supports the previously made observation that the Tc2 genotype contributes 
to X-ALD phenotype generation.  
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Search terms: [95] Association studies in genetics; [155] Leukodystrophies; [159] 
Peroxisomes; [153] Metabolic disease (inherited)
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Introduction 
X-linked adrenoleukodystrophy (X-ALD, OMIM #300100) is caused by defects of the 
ABCD1 gene on chromosome Xq28 resulting in an impairment of peroxisomal beta-oxidation 
and the accumulation of saturated very long chain fatty acids (VLCFA). The minimum 
frequency of hemizygotes plus heterozygotes is 1:16,800 in the United States, suggesting that 
X-ALD is the most common inherited leukodystrophy [3]. 
X-ALD is characterized by a highly variable clinical spectrum. It ranges from cerebral 
demyelinating, inflammatory childhood phenotypes associated with a poor prognosis 
(CCALD), over milder adulthood disease with focal demyelination in the central nervous 
system (ACALD), to adulthood forms without central nervous system demyelination and 
considerably slower symptom progression (AMN). The appearance of cerebral demyelination 
is crucial for the phenotype, prognosis and therapy of X-ALD. The development of the 
phenotype can not be predicted by biochemical factors like levels of VLCFA. In addition, no 
genotype/phenotype correlation has been established [13]. Even within closely related patients 
the clinical course may range widely. Thus, yet unidentified modifier genes or other co-
factors are likely to modulate the phenotypic variation and disease severity [5-8]. 
One possible X-ALD disease modifier might be methionine metabolism. Methionine 
metabolism plays a crucial role in DNA methylation and in providing methyl groups 
necessary for building brain myelination. It is also involved in the generation of glutathione 
that is necessary for defense against oxidative stress and in the regulation of inflammatory 
processes [15]. The metabolism is of marked inter-individual variety due to the existence of 
functionally relevant polymorphisms and differences in vitamin availability, which are 
important cofactors in methionine metabolism (vitamin B12, B6, folic acid). We have 
previously reported that polymorphisms of methionine metabolism are associated with the 
clinical phenotype of X-ALD. The insertion allele of cystathionine beta-synthase (CBS) 
c.844_845ins68 was significantly more common in AMN patients than in the cerebral 
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demyelinating forms CCALD and ACALD in a sample of 86 Dutch and German patients 
[12]. In addition to that, the GG genotype of transcobalamin 2 (Tc2) c.776C>G was more 
common in ACALD than in AMN, and a combined risk genotype was more common in 
ACALD than in AMN. The combined risk genotype was defined as: presence of at least one 
of the genotypes transcobalamin 2 (Tc2) c.776C>G (GG), methylenetetrahydrofolate 
reductase (MTHFR) c.677C>T (TT) or methionine synthase (MTR) c.2756A>G (AG/GG) 
[9]. Here we studied the genotypes of 172 additional X-ALD patients to retest our previous 
data. 
 
Materials and Methods 
Patients 
We analyzed 172 DNA samples: 34 DNA samples from China (CCALD: n=21; ACALD: 
n=9; AMN: n=4), 110 samples from France (CCALD: n=50; ACALD: n=25; AMN: n= 35), 8 
DNA samples from Germany (ACALD: n=4; AMN: n=4) and 20 samples from the USA 
(CCALD: n=11; AMN: n=9). Patients from China were of Han ethnicity, patients from 
France, Germany and USA of Caucasian origin. All patients or their trustees have given 
written informed consent. The study was approved by the local ethical committees. 
 
Genotyping 
Genomic DNA prepared from peripheral leukocytes was used for genotyping by PCR 
amplification and restriction analysis of eight genetic variants of methionine metabolism 
including the intronic deletion dihydrofolate reductase (DHFR) c.594+59del19bp (affecting 
the transcript level; GenBank NM_000791.3), the splice alteration cystathionine beta-synthase 
(CBS) c.844_855ins68 (affecting the transcript level; GenBank S78267.1), and the missense 
mutations (i.e., leading to amino acid exchanges) methionine synthase (MTR) c.2756A>G 
(p.D919G; rs1805087), methylenetetrahydrofolate reductase (MTHFR) c.677C>T (p.A222V; 
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rs1801133) and c.1298A>C (p.E429A; rs1801131), methionine synthase reductase MTRR 
c.60A>G, reduced folate carrier 1 (RFC1) c.80G>A (p.R27H; rs1051266 ), and 
transcobalamin 2 (Tc2) c.776C>G (p.P259R; rs1801198).[10] 
 
Statistics 
The association of genotypes and phenotypes was analyzed with univariate two sided 
Pearson`s χ2 tests. As this is a confirmatory study, we did not correct for multiple testing. 
 
Results 
Analyses with two degrees of freedom (all genotypes) revealed an association of the G-allele 
of Tc2 c.776C>G with the X-ALD phenotype in the comparison between AMN and CCALD 
(2=6.09; p=0.048), but not in the comparison between AMN and the pooled demyelinating 
phenotypes CCALD+ACALD, 2=4.74; p=0.093. The other polymorphisms did not reveal 
significant associations in this study sample (table 1). If only the Caucasian patients without 
the patients from China or subgroups divided by populations were analyzed, the differences of 
the frequencies of the Tc2 genotype in different X-ALD phenotypes were not significant (not 
shown). The prevalence of the GG-genotype of Tc2 c.776C>G was higher in patients with 
CNS demyelination than in those without CNS-demyelination (2=4.42; p=0.036). 
Additionally, the GG- genotype was more frequent in patients with the most severe 
phenotype, CCALD, than in patients with AMN (2=4.71; p=0.031) (table 2).  
 
Discussion 
In the present study consisting of 172 patients with CCALD, ACALD and AMN we found 
that the G-allele of the Tc2 c.776C>G polymorphism is associated with the occurrence of 
CNS demyelination in X-ALD patients. The G-allele of Tc2 c.776C>G leads to the amino 
acid substitution p.P259R that seems to affect the affinity of the transcobalamin 2 protein to 
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vitamin B12 and the ability to transport vitamin B12 into tissues [1, 2, 4]. Vitamin B12 is 
necessary to synthesize S-adenosylmethionine, which serves as methyl group donor for CNS 
myelination. Accordingly, vitamin B12 deficiency can lead to demyelination of the central 
nervous system in otherwise healthy individuals [16].  
 
Methotrexate is a widely used chemotherapeutic drug, which may lead to neurotoxic side-
effects accompanied by cerebral white matter changes. Methotrexate reduces the vitamin 
B12-dependent synthesis of S-adenosylmethionine in the central nervous system [14]. In a 
series of 68 patients treated with methotrexate the G-allele and the GG-genotype of Tc2 
c.776C>G were associated with the occurrence of white matter changes of the brain [11]. We 
conclude that it is unlikely that the GG-genotype of Tc2 c.776C>G is the main determinant of 
the different X-ALD phenotypes. This observation may serve as an indicator of the role of the 
methionine metabolism in X-ALD disease progression in general. We speculate that the 
influence of the GG-genotype of Tc2 c.776C>G on functional availability of vitamin B12 and 
of SAM synthesis may dispose X-ALD patients to demyelination of the central nervous 
system. 
 
In a previous study with a sample of 86 Dutch and German patients, we observed an 
association of X-ALD phenotypes with additional genetic variants of the methionine 
metabolism [9, 12]. In the actual sample we only confirmed the association of the G-allele of 
the polymorphism Tc2 c.776C>G with the occurrence of CNS demyelination in X-ALD 
patients, whereas the other previous observations were not confirmed. We can not completely 
exclude differences between the previous and the actual patient samples that might have 
contributed to the differences in the results. Dietary influences concerning the uptake of 
amino acids or vitamins may speculatively modify effects of the analyzed polymorphisms on 
X-ALD phenotype generation, and dietary conditions might have differed between the old and 
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the new patient sample. However, we conclude that only the influence of the Tc2 
polymorphism is validated regarding the results of the present study, whereas the other 
previously reported findings have to be assumed as false positive as long as they are not 
confirmed in an additional X-ALD patient sample. 
 
These data are limited as the association is of weak significance. If corrected for multiple 
testing or if analyzed in subgroups divided by populations or ethnicity, the results were not 
significant. However, this study was of confirmative character, and as the results concerning 
the Tc2 variant confirmed our previous observations in an independent sample of X-ALD 
patients, we consider the influence of the Tc2 c.776C>G variant on phenotype generation in 
X-ALD as confirmed.  
 
It seems warranted to examine the effect of experimentally induced vitamin B12, folate and 
SAM depletion in addition to vitamin B12, folate and SAM substitution on the phenotype of 
X-ALD mouse models to estimate whether clinical studies investigating the effect of vitamin 
or SAM substitution on the clinical course of X-ALD are justified.  
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Table 1: All analysed polymorphisms and X-ALD phenotypes 
 
 
Tc2  
c.776C>G 
CC CG GG CCALD vs. AMN CCALD+ACALD 
vs. AMN 
CCALD 0.19 0.42 0.39 
ACALD 0.34 0.32 0.34 
AMN 0.35 0.44 0.21 
p=0.048 
 
p=0.093 
      
MTR  
c.2756A>G 
AA AG GG CCALD vs. AMN CCALD/ACALD 
vs. AMN 
CCALD 0.72 0.25 0.03 
ACALD 0.78 0.22 0 
AMN 0.69 0.31 0 
p=0.364 
 
p=0.393 
 
      
MTHFR 
c.677C>T 
CC CT TT CCALD vs. AMN  CCALD+ACALD 
vs. AMN 
CCALD 0.42 0.39 0.19 
ACALD 0.31 0.53 0.16 
AMN 0.40 0.42 0.18 
p=0.940 
 
p=0.970 
 
      
MTHFR 
c.1298A>C 
AA AC CC CCALD vs. AMN  CCALD+ACALD 
vs. AMN 
CCALD 0.59 0.33 0.08 
ACALD 0.42 0.53 0.05 
AMN 0.51 0.41 0.08 
p=0.721 
 
p=0.964 
 
      
CBS 
c.844_845ins68 
dd di ii CCALD vs. AMN CCALD+ACALD 
vs. AMN 
CCALD 0.89 0.11 0 
ACALD 0.89 0.11 0 
AMN 0.89 0.11 0 
p=0.659 
 
p=0.989 
 
      
MTRR  
c.60A>G 
AA AG GG CCALD vs. AMN CCALD+ACALD 
vs. AMN 
CCALD 0.14 0.42 0.44 
ACALD 0.24 0.54 0.22 
AMN 0.15 0.57 0.28 
p=0.226 
 
p=0.502 
 
      
RFC1  
c.80G>A 
GG AG AA CCALD vs. AMN  CCALD+ACALD 
vs. AMN 
CCALD 0.31 0.47 0.22 
ACALD 0.27 0.43 0.30 
AMN 0.33 0.46 0.21 
p=0.948 
 
p=0.822 
 
      
DHFR 
c.594+59del19b
p 
dd di ii CCALD vs. AMN  CCALD+ACALD 
vs. AMN 
CCALD 0.14 0.51 0.35 p=0.253 p=0.238 
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ACALD 0.12 0.54 0.34 
AMN 0.06 0.48 0.46 
 
 
Table 1: Result of all polymorphisms analysed and X-ALD phenotypes CCALD (n=82), 
ACALD (n=38), and AMN (n=52).  
 
 
 
Table 2: Tc2 c.776-GG genotypes and X-ALD phenotypes 
 
 
Tc2  
c.776C>G 
CC/ 
CG 
GG  pure AMN vs. 
CCALD 
pure AMN vs. 
CCALD+ALMN 
CCALD 0.61 0.39  
ACALD 0.66 0.34  
AMN 0.79 0.21  
p=0.031 p=0.036 
 
 
Table 2: Tc2 c.776-GG genotype and X-ALD phenotypes CCALD (n=82), ACALD (n=38), 
and AMN (n=52).  
. 
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